As MDR is usually related to the increased expression of MDR transporters, the combination of chemotherapeutic drugs with agents capable of inhibiting ABC transporters represent a logical and attractive strategy to overcome MDR in cancer chemotherapy. Here, ABCG2 is linked to cancer.